N@N

Gene E. Burleson, Healthcare Industry Executive and Director of Several NYSE-Listed Companies, Joins Vyteris Board of Directors

_{//health-fitness.news-articles.net/content/2010/ .. -companies-joins-vyteris-board-of-directors.html}
^{Published in Health and Fitness on Thursday, December 16th 2010 at 5:10 GMT by Market Wire}  

FAIR LAWN, N.J.--([ BUSINESS WIRE ])--Vyteris, Inc. (OTCBB: VYTR), an innovator in alternative drug delivery technology, announces that Gene E. Burleson (age 69) has been appointed to the Companya™s Board of Directors effective December 1, 2010. Mr. Burleson is the first of two MediSync BioServices Directors to be named to the Vyteris Board under the September 2010 merger agreement.

"Genea™s vast experience in the healthcare industry will be instrumental in achieving our strategic and operational goals in the rapidly expanding contract drug development industry."

aWe are delighted to welcome Gene to the Vyteris Board of Directors, and are confident his experience in building and consolidating healthcare services companies over a career spanning more than 30 years will be invaluable as we integrate MediSync BioServices with our active transdermal drug delivery business,a stated Haro Hartounian, Ph.D., President and CEO of Vyteris. aGenea™s vast experience in the healthcare industry will be instrumental in achieving our strategic and operational goals in the rapidly expanding contract drug development industry.a

Mr. Burleson served as Chairman (1989-1997) and CEO and President (1990-1997) of GranCare, Inc., which, under his management, grew from under $10 million in revenue to become one of the nationa™s largest publicly-traded long-term healthcare providers with revenues in excess of $1 billion. Following the merger of GranCarea™s pharmacy operations with Vitalink Pharmacy Services, he served as CEO and a Director of Vitalink a provider of pharmacy services to skilled nursing facilities. Both GranCare and Vitalink were NYSE-listed companies.

He has an extensive and successful track record of consolidation within the healthcare industry. In 2006, along with other established life science executives, Mr. Burleson joined MediSync, a consolidator of complementary, high-value, niche contract research organizations, site management organizations and related businesses.

Mr. Burleson currently serves on the Board of Directors of SunLink Health Systems. Previously he served as Chairman and CEO of Pet DRx Corporation, as Chairman of Mariner Post-Acute Network and Alterra Healthcare Corporation, and as a Director of Deckers Outdoor Corporation and Prospect Medical Holdings, among others. He holds a BS in Accounting and an MBA from East Tennessee State University.

About Vyteris

Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing clearance from the U.S. Food and Drug Administration. Vyteris' proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology is intended to allow precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economic, and lifestyle advantages over existing methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where the Company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit [ www.vyteris.com ].

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.